Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

PILANCI, Kezban; Saglam, Sezer; Okyar, ALPER; YÜCEL, Serap; Pala-Kara, ZELİHA; Ordu, Cetin; Namal, Esat; CIFTCI, Rumeysa; Iner-Koksal, Ulkuhan; Kaytan-Saglam, Esra

doi:10.1007/s00280-016-3067-x

Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., ...Daha Fazla

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.78, sa.1, ss.143-150, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 78 Sayı: 1
Basım Tarihi: 2016
Doi Numarası: 10.1007/s00280-016-3067-x
Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.143-150
İstanbul Üniversitesi Adresli: Evet

Özet

The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer.